Tanvex Biopharma Inc. (6541) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Tanvex Biopharma Inc. (6541:TWSE), powered by AI.

Current Price
$40.45
Sector
Healthcare
What is the Tanvex Biopharma Inc. stock price forecast?

Tanvex Biopharma Inc. is currently trading at $40.45. View real-time AI analysis on Alpha Lenz.

What is Tanvex Biopharma Inc. insider trading activity?

View the latest insider trading data for Tanvex Biopharma Inc. on Alpha Lenz.

What is Tanvex Biopharma Inc.'s P/E ratio?

View Tanvex Biopharma Inc.'s valuation metrics on Alpha Lenz.

Tanvex Biopharma Inc.

TWSE · 6541
NT$40.45-0.05(-0.12%)
Ask about Tanvex Biopharma Inc.'s future dividend policy...
Alpha Chat Insight

Tanvex Biopharma Inc.'s ROE is -45.5%. Explore profitability and growth together.

Ask for details

Company Overview

Tanvex Biopharma Inc. is a biopharmaceutical company focused on the development, manufacturing, and commercialization of biosimilar drugs. Biosimilars are pharmaceuticals that are highly similar to already approved biologic drugs, offering comparable quality, safety, and efficacy. Tanvex Biopharma plays a pivotal role in the healthcare sector by providing more affordable therapies to patients, thus addressing the growing demand for cost-effective treatment options. The company's portfolio includes biosimilars for the treatment of cancer, autoimmune diseases, and other chronic conditions, primarily targeting high-demand therapeutic areas known for their biologic drug utilization. Through its advanced manufacturing capabilities and strategic focus on regulatory compliance, Tanvex Biopharma aims to deliver high-quality biosimilar products. The company's operations and innovations significantly contribute to the biopharmaceutical market, enhancing competitive access to vital medications and potentially easing the financial burden on healthcare systems globally. Tanvex Biopharma Inc.'s commitment to innovation in biologics marks a noteworthy presence and influence in the biopharma industry.

CEOMr. Stephen Lam
SectorHealthcare
IndustryBiotechnology
Employees200

Company Statistics

FY 2025

Profile

N/AMarket Cap
NT$400.97MRevenue
0.00Shares Out
200Employees

Margins

-109.91%Gross
-270.04%EBITDA
-344.59%Operating
-374.89%Pre-Tax
-374.13%Net

Valuation

N/AP/E
N/AP/B
N/AEV/Sales
N/AEV/EBITDA
N/AP/FCF

Growth (CAGR)

161.57%Rev 3Yr
321.89%Rev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

-28.05%ROA
-45.55%ROE
-27.22%ROIC

Financial Health

NT$878.71MCash & Cash Equivalents
NT$1.39BNet Debt
39.82%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Tanvex Biopharma Inc. (ticker: 6541) is a company listed on TWSE in the Healthcare sector (Biotechnology). It has approximately 200 employees.

The current price is 40.45 with a P/E ratio of -x and P/B of -x.

ROE is -45.55% and operating margin is -344.59%. Annual revenue is $401M.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Tanvex Biopharma Inc. (6541) Stock Forecast 2026 $40.45 — Price, Financials & Analyst Targets | Alpha Lenz